Caspofungin is the first echinocandin antifungal drug. It has a broad antibacterial spectrum, a long half-life, a high binding rate to human serum proteins, and a few adverse reactions. It is known as the trump card in the systemic antifungal drug market. The drug is an anti-fungal infection drug currently recommended by clinical guidelines in various countries and is widely marketed worldwide. Caspofungin was originally developed by Merck Sharp & Dohme. It was launched in the United States and Europe in 2001. It was launched in China under the trade name CANCIDAS in 2002. By 2020, Caspofungin has been included in China’s Class B medical insurance. There are 4 manufacturers in the Chinese market in 2020, which are Merck Sharp & Dohme (IA) Corp, Merck Sharp & Dohme Ltd, Jiangsu Hengrui Medicine Co., Ltd., and Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
According to CRI’s market research, the sales value of Caspofungin in the Chinese market increased year by year from 2016 to 2019. Due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the sales value of Caspofungin in the Chinese market decreased to CNY 801 million in 2020 and the CAGR of Caspofungin in sales value from 2016 to 2020 is 15.45%.
CRI expects that with the relief of COVID-19, the sales of Caspofungin in the Chinese market will have a restorative growth from 2021 to 2025. In addition, Caspofungin has the characteristics of broad antifungal spectrum, excellent curative effect and high safety. Based on these advantages, the sales value and sales volume of Caspofungin in the Chinese market still has room to rise. By the first half of 2021, in addition to the original research companies, a total of 5 domestic companies have been approved, including Huadong Medicine Co.,Ltd., Borui Pharmaceutical Technology Development Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Haisco Pharmaceutical Group Co., Ltd. It is expected that with the addition of new manufacturers, the sales value of Caspofungin will continue to rise.
- -The impact of COVID-19 on China’s Caspofungin market
- – Sales value of China’s Caspofungin 2016-2020
- – Competitive landscape of China’s Caspofungin market
- – Prices of Caspofungin in China
- – Prices of Caspofungin in China by regions and manufacturers
- – Analysis on factors affecting the development of China’s Caspofungin market
- – Prospect of China’s Caspofungin market from 2021 to 2025